-
Something wrong with this record ?
Effects of necrostatin-1, an inhibitor of necroptosis, and its inactive analogue Nec-1i on basal cardiovascular function
A. Szobi, T. Rajtik, A. Adameova,
Language English Country Czech Republic
Document type Journal Article
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- Electrocardiography MeSH
- Imidazoles pharmacology MeSH
- Indoles pharmacology MeSH
- Blood Pressure drug effects MeSH
- Random Allocation MeSH
- Rats, Wistar MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Inhibition of receptor-interacting serine/threonine-protein kinase 1 (RIP1) by necrostatin-1 (Nec-1) alleviates cardiac injury due to prevention of necroptotic cell death. Its inactive analogue necrostatin-1i (Nec-1i), lacking RIP1 activity, serves as a suitable control. It is unknown if these agents influence the heart function in the absence of damaging stimuli. For this purpose, we measured intraarterial blood pressure (systolic - sBP and diastolic - dBP) and ECG parameters after a bolus administration of Nec-1 and Nec-1i in rats during 30 min. Nec-1, unlike Nec-1i, increased sBP and dBP, as well as heart rate reaching the peak at 20 min. The P wave duration tended to be decreased and the duration of the PR interval was shortened by Nec-1 indicating faster conduction of the impulses through atria to the ventricles. The drugs did not influence the QTc interval duration and no episode of ventricular arrhythmia was observed. In summary, Nec-1 temporarily modulates blood pressure and electrical function of the healthy heart. These effects of Nec-1 are likely due to its off-target action or RIP1 has an important role in the regulation of cardiovascular function independently of its action on the necroptotic pathway.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17012767
- 003
- CZ-PrNML
- 005
- 20170425105017.0
- 007
- ta
- 008
- 170412s2016 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.933393 $2 doi
- 035 __
- $a (PubMed)27875900
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Szobi, Adrian. $u Comenius University in Bratislava, Faculty of Pharmacy, Department of Pharmacology and Toxicology, Bratislava, Slovak Republic $7 xx0307133
- 245 10
- $a Effects of necrostatin-1, an inhibitor of necroptosis, and its inactive analogue Nec-1i on basal cardiovascular function / $c A. Szobi, T. Rajtik, A. Adameova,
- 520 9_
- $a Inhibition of receptor-interacting serine/threonine-protein kinase 1 (RIP1) by necrostatin-1 (Nec-1) alleviates cardiac injury due to prevention of necroptotic cell death. Its inactive analogue necrostatin-1i (Nec-1i), lacking RIP1 activity, serves as a suitable control. It is unknown if these agents influence the heart function in the absence of damaging stimuli. For this purpose, we measured intraarterial blood pressure (systolic - sBP and diastolic - dBP) and ECG parameters after a bolus administration of Nec-1 and Nec-1i in rats during 30 min. Nec-1, unlike Nec-1i, increased sBP and dBP, as well as heart rate reaching the peak at 20 min. The P wave duration tended to be decreased and the duration of the PR interval was shortened by Nec-1 indicating faster conduction of the impulses through atria to the ventricles. The drugs did not influence the QTc interval duration and no episode of ventricular arrhythmia was observed. In summary, Nec-1 temporarily modulates blood pressure and electrical function of the healthy heart. These effects of Nec-1 are likely due to its off-target action or RIP1 has an important role in the regulation of cardiovascular function independently of its action on the necroptotic pathway.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a krevní tlak $x účinky léků $7 D001794
- 650 _2
- $a elektrokardiografie $7 D004562
- 650 _2
- $a imidazoly $x farmakologie $7 D007093
- 650 _2
- $a indoly $x farmakologie $7 D007211
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a náhodné rozdělení $7 D011897
- 650 _2
- $a potkani Wistar $7 D017208
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Rajtík, Tomáš $7 xx0307132 $u Comenius University in Bratislava, Faculty of Pharmacy, Department of Pharmacology and Toxicology, Bratislava, Slovak Republic
- 700 1_
- $a Adameová, Adriana $7 xx0064778 $u Comenius University in Bratislava, Faculty of Pharmacy, Department of Pharmacology and Toxicology, Bratislava, Slovak Republic
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 65, č. 5 (2016), s. 861-865
- 856 41
- $u http://www.biomed.cas.cz/physiolres/ $y domovská stránka časopisu
- 910 __
- $a ABA008 $b A 4120 $c 266 $y 4 $z 0
- 990 __
- $a 20170412 $b ABA008
- 991 __
- $a 20170421142035 $b ABA008
- 999 __
- $a ok $b bmc $g 1201945 $s 973540
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 65 $c 5 $d 861-865 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- LZP __
- $b NLK118 $a Pubmed-20170412